A study in healthy people to compare how 2 different formulations of survodutide are taken up by the body

2025-522325-35-00 Protocol 1404-0103 Human pharmacology (Phase I) - Other Ongoing, recruitment ended

Start 27 Oct 2025 · Status Ongoing, recruitment ended · 1 EU/EEA countries · 2 sites · Protocol 1404-0103

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruitment ended
Participants planned 100
Countries 1
Sites 2

Healthy volunteer trial

Key facts

Sponsor
Boehringer Ingelheim International GmbH
Participant type
Healthy volunteers
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Not possible to specify
Trial duration
27 Oct 2025 → ongoing
Decision date (initial)
2025-09-02
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2025-522325-35-00
WHO UTN
U1111-1322-4700

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Healthy volunteer trial

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Boehringer Ingelheim International GmbH

Sponsor organisation
Boehringer Ingelheim International GmbH
Address
Binger Strasse 173
City
Ingelheim Am Rhein
Postcode
55216
Country
Germany

Scientific contact point

Organisation
Boehringer Ingelheim International GmbH
Contact name
CT Disclosure & Data Transparency

Public contact point

Organisation
Boehringer Ingelheim International GmbH
Contact name
CT Disclosure & Data Transparency

Locations

1 EU/EEA country · 2 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ongoing, recruitment ended 100 2
Rest of world 0

Investigational sites

Germany

2 sites · Ongoing, recruitment ended
CRS Clinical Research Services Berlin GmbH
n/a, Siemensdamm 65, Siemensstadt, Berlin
CRS Clinical Research Services Management GmbH
n/a, Grenadierstrasse 1, Neckarstadt, Mannheim

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2025-10-27 2025-11-05 2025-12-16

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-07-23 Germany Acceptable
2025-09-01
2025-09-02
2 SUBSTANTIAL MODIFICATION SM-1 2025-09-18 Germany Acceptable 2025-10-20
3 SUBSTANTIAL MODIFICATION SM-2 2026-01-28 Germany Acceptable
2026-02-06
2026-02-11